Published in Drug Des Devel Ther on September 09, 2015
Effect of the Lipoxygenase Inhibitor Baicalein on Muscles in Ovariectomized Rats. J Nutr Metab (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osteoclast differentiation and activation. Nature (2003) 18.59
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 13.53
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Developmental regulation of the growth plate. Nature (2003) 11.53
Extended longevity in mice lacking the insulin receptor in adipose tissue. Science (2003) 8.53
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
Control of osteoblast function and regulation of bone mass. Nature (2003) 5.06
Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev (1989) 3.87
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
The complexities of skeletal biology. Nature (2003) 2.21
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem (2008) 1.38
The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex (2009) 1.34
An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development (2011) 1.27
Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy (2000) 1.19
A review of anabolic therapies for osteoporosis. Arthritis Res Ther (2003) 1.14
mTORC1 signaling controls mammalian skeletal growth through stimulation of protein synthesis. Development (2014) 1.08
Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med (2002) 1.06
Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol (1987) 1.01
IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab (2008) 1.01
Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res (2011) 1.01
Protective effects of baicalein on tert-butyl hydroperoxide-induced hepatic toxicity in rat hepatocytes. J Biomed Sci (2005) 0.95
Association of functionally different RUNX2 P2 promoter alleles with BMD. J Bone Miner Res (2005) 0.94
Baicalein inhibition of oxidative-stress-induced apoptosis via modulation of ERKs activation and induction of HO-1 gene expression in rat glioma cells C6. Toxicol Appl Pharmacol (2006) 0.94
Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem Toxicol (2008) 0.93
Alleles of RUNX2/CBFA1 gene are associated with differences in bone mineral density and risk of fracture. J Bone Miner Res (2002) 0.92
Correlation of common biochemical markers for bone turnover, serum calcium, and alkaline phosphatase in post-menopausal women. Malays J Med Sci (2014) 0.91
Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids. J Biochem (1990) 0.90
Baicalein stimulates osteoblast differentiation via coordinating activation of MAP kinases and transcription factors. J Cell Biochem (2008) 0.88
Association of a RUNX2 promoter polymorphism with bone mineral density in postmenopausal Korean women. Calcif Tissue Int (2009) 0.88
Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women. Bone (2010) 0.86
Inhibition of inducible nitric oxide synthase expression by baicalein in endotoxin/cytokine-stimulated microglia. Biochem Pharmacol (2004) 0.86
RUNX2 alleles associated with BMD in Scottish women; interaction of RUNX2 alleles with menopausal status and body mass index. Bone (2004) 0.86
Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling. Stem Cells (2013) 0.85
Baicalein inhibits Raf-1-mediated phosphorylation of MEK-1 in C6 rat glioma cells. Eur J Pharmacol (2003) 0.82
Baicalein: an in vitro antigenotoxic compound from Scutellaria baicalensis. Planta Med (2000) 0.77
Age and menopausal status affect osteoprotegerin and osteocalcin levels in women differently, irrespective of thyroid function. Clin Med Insights Endocrinol Diabetes (2014) 0.77